图尼卡米辛C与潜在蛋白质标相互作用的计算建模:从反向对接与分子动态模拟的角度来看
Vivash Naidoo1,2, Ikechukwu Achilonu3, Sheefa Mirza1
1Department of Internal Medicine, Medicine, Wits/MRC Common Epithelial Cancer Research Centre, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
Current issues in molecular biology
|July 23, 2025
概括
图尼卡米辛C显示了结直肠癌 (CRC) 治疗的潜力,通过抑制关键蛋白质提米丁激酶1 (TK1) 和cAMP依赖的蛋白激酶催化子单元α (PKAc) 来抑制结直肠癌 (CRC). 这项研究确定了这些蛋白质是CRC的新疗法标.
科学领域:
- 生物化学和分子生物学
- 癌症研究 癌症研究
- 计算生物学 计算生物学
背景情况:
- 蛋白质糖化在癌症中至关重要,影响细胞信号传递,免疫反应和转移.
- 向糖基化提供了通过破坏癌症进展机制的治疗潜力.
- 尼卡米辛C是一种糖化酶抑制剂,在乳腺癌中表现有前途,但在结肠直肠癌 (CRC) 中尚未研究.
研究的目的:
- 研究尼卡米辛C在结肠直肠癌 (CRC) 中的潜在治疗作用.
- 通过使用in silico方法在CRC中识别突尼卡米辛C的潜在药物标.
主要方法:
- 利用HTDocking,基因本体学 (GO) 和KEGG通路分析来识别标蛋白.
- 采用分子动力学 (MD) 建模来分析图尼卡米辛C结合及其对蛋白质结构和活性的影响.
- 进行了连续验证研究,以确认结合部位相互作用和亲和力.
主要成果:
- 确定了提米丁激酶1 (TK1) 和cAMP依赖的蛋白激酶催化子单元α (PKAc) 作为图尼卡米辛C的标.
- 医学模拟显示,图尼卡米辛的C结合会诱导形状变化,抑制TK1和PKAc的活性.
- 图尼卡米辛C在TK1和PKAc.的疏水口袋中表现出高的结合亲和力.
结论:
- 图尼卡米辛C有效地结合并抑制TK1和PKAc,这表明CRC的治疗潜力.
- TK1和PKAc被确定为癌症治疗中开发糖化酶抑制剂的新目标.
- 这项研究为重新利用抑制剂和发现CRC的新治疗策略提供了基础.
关键词:
结肠直肠癌 (CRC) 是一种癌症.尼卡米辛是一种尼卡米辛.葡萄糖酶化是什么? 葡萄糖酶化是什么?在技术中.分子动力学分子动力学蛋白质激酶A是一种蛋白质激酶.治疗目标是治疗的目标.提米丁激酶 1 的作用.更多相关视频
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
540
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.9K
相关概念视频
02:04Protein-protein Interfaces
13.3K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.3K
01:16Protein-Drug Binding: Mechanism and Kinetics
966
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
966